Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23778486 | 0.94 | AKT1 (0.45) | AKT1CYP17A1AKT2PDE2ACYP19A1 | |
| SCHEMBL89721 | 0.85 | SSTR4 (0.50) | AKT1AKT2CNR1CNR2SSTR4 | |
| SCHEMBL12583795 | 0.83 | DRD2 (0.51) | AKT1AKT2SLC6A9CNR1CNR2 | |
| SCHEMBL1141296 | 0.83 | NPC1 (0.45) | AKT1AKT2PDE2ASSTR4RAB9A | |
| SCHEMBL17040898 | 0.82 | SSTR4 (0.47) | AKT1AKT2SLC6A9CNR1CNR2 | |
| SCHEMBL17321373 | 0.82 | RORC (0.41) | AKT1AKT2PDE2ASSTR4DRD2 | |
| SCHEMBL6211955 | 0.82 | MAPT (0.46) | AKT1AKT2PDE2ACNR1CNR2 | |
| SCHEMBL14161397 | 0.81 | AKT1 (0.42) | AKT1AKT2SLC6A9PDE2ACNR1 | |
| SCHEMBL17321836 | 0.81 | AKT1 (0.40) | AKT1AKT2PDE2ACNR1CNR2 | |
| SCHEMBL17321812 | 0.81 | AKT1 (0.40) | AKT1AKT2LMNARAB9ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | AKT1 4747/4885CYP17A1 556/4885AKT2 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.